JANX Janux Corp Company Short-Term Debt

Janux Therapeutics, Inc. - graphic logo of issuer JANX

Janux Therapeutics (JANX) retains a staff of rare oncology experts through a stock option system that prevents talent attrition. The business relies on the implementation of the innovative TRACTR system to create high-demand anti-tumor drugs and secure future contracts with industry behemoths. This chart on GURU.Markets shows the 0.00 metric, while investors should consider the high cash burn rate and the uncertainty of early-stage test outcomes.

JANX januxrx.com Short-Term Debt (07/04/2022 - 11/01/2026)

Analytical breakdowns and data insights for company Janux Corp (JANX)

- current quotes and average value forecast:
Price Chart Janux Therapeutics, Inc.|JANX - Average Forecast Price
- market capitalization data:
Market Value Janux Therapeutics, Inc.|JANX - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Janux Therapeutics|JANX - Total Stockholders' Equity|Market Capitalization to Book Value Ratio januxrx.com|JANX - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Janux Therapeutics|JANX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Janux Therapeutics|JANX - Aggregate Debt Obligations|Debts to Book Capitalization Janux Therapeutics, Inc.|JANX - Long-Term Debt Volume|Company Short-Term Debt Janux Therapeutics|Quick Liquidity januxrx.com
- earnings and multiples data:
JANX - Net Income
General company analysis:Janux Therapeutics, Inc. (JANX)
Flagship merchandise of januxrx.com

Janux Therapeutics (JANX) lacks pricing power, as its valuation is based exclusively on clinical trial results. This indicator measures the volume of obligations with a maturity of up to one year, determining the speed of current debt servicing. Investors view this balance as a liquidity risk in the absence of commercial sales. Reducing this burden lowers the probability of default but may signal a reduction in R&D. The time series of short-term debt clearly captures these financial fluctuations.

Competitors of Janux Therapeutics

IBRX - Company Short-Term Debt|Short-Term Debt Immunocore Holdings|Arcus Bio (RCUS) - Company Short-Term Debt|ZYME (Zymeworks Biopharmaceuticals) - Company Short-Term Debt|Company Short-Term Debt Tango Therapeutics|Short-Term Debt iovance.com IOVA|Company Short-Term Debts IMTX|Xencor Inc (XNCR) - Short-Term Indebtedness|Compass Bio - Company Current Liabilities|Replimune Inc. (REPL) - Short-Term Debt|LYEL: Company Current Liabilities|Company Short-Term Loans and Borrowings IPHA (innate-pharma.com)|PYXS: Company Short-Term Debts|CGEN - Short-Term Debt Volume|Company Short-Term Debt IO Biotech Corp|Company Current Liabilities Sutro Biopharma, Inc (STRO)|Company Short-Term Debt MiNK Therapeutics, Inc. (INKT)|Company Current Liabilities werewolftx.com HOWL|Immix Biopharma - Company Current Liabilities|Company Short-Term Debts alxoncology.com ALXO|CUE - Company Short-Term Debt|PDSB (PDS Biotechnology) - Company Short-Term Indebtedness|sonnetbio.com (SONN) - Company Short-Term Debt|Short-Term Debt MAIABiotech.com (MAIA)|Company Current Liabilities LIMN|LVTX - Short-Term Indebtedness|Company Current Liabilities NXTC (NextCure Corp)|Amount of Current Liabilities LPTX|Company Short-Term Debts INTS (Intensity Therapeutics, Inc.)|Company Short-Term Loans and Borrowings SNSE|Theriva Biologics - Company Short-Term Debts|Short-Term Debt Gritstone bio, Inc.|Kineta Bio (KA) - Company Short-Term Debt|NexImmune Corporation - Company Short-Term Loans and Borrowings|TSBX (Turnstone Biologics Corp) - Company Short-Term Debts|Company Short-Term Debts vaccinex.com|Company Short-Term Debt Harpoon Therapeutics, Inc. (HARP)